Valeant Pharmaceuticals International Inc. (NYSE:VRX) received a $29.00 price objective from stock analysts at RBC Capital Markets in a research report issued to clients and investors on Wednesday. The brokerage presently has a a “sector perform” rating on the specialty pharmaceutical company’s stock. RBC Capital Markets’ price objective would indicate a potential upside of 72.41% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. Rodman & Renshaw restated a “buy” rating and issued a $90.00 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday, July 28th. Jefferies Group restated a “buy” rating and issued a $40.00 price target on shares of Valeant Pharmaceuticals International in a research report on Wednesday, August 10th. Guggenheim restated a “buy” rating and issued a $55.00 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 11th. TD Securities restated a “buy” rating and issued a $38.00 price target on shares of Valeant Pharmaceuticals International in a research report on Saturday, August 13th. Finally, Morgan Stanley set a $33.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Wednesday, August 3rd. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $40.18.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) opened at 16.82 on Wednesday. The stock’s market capitalization is $5.85 billion. Valeant Pharmaceuticals International has a 12 month low of $13.77 and a 12 month high of $119.87. The company has a 50 day moving average price of $22.29 and a 200 day moving average price of $25.33.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.78 by $0.23. The business earned $2.48 billion during the quarter, compared to analyst estimates of $2.49 billion. Valeant Pharmaceuticals International had a positive return on equity of 41.02% and a negative net margin of 22.17%. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.74 EPS. Equities research analysts predict that Valeant Pharmaceuticals International will post $6.45 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its position in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares during the period. Kistler Tiffany Companies LLC raised its position in shares of Valeant Pharmaceuticals International by 95.5% in the third quarter. Kistler Tiffany Companies LLC now owns 5,567 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 2,719 shares during the last quarter. US Bancorp DE raised its position in shares of Valeant Pharmaceuticals International by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares during the last quarter. Cacti Asset Management LLC raised its position in shares of Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock worth $169,000 after buying an additional 3,400 shares during the last quarter. Finally, AGF Investments Inc. raised its position in shares of Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock worth $178,000 after buying an additional 4,857 shares during the last quarter. Hedge funds and other institutional investors own 64.39% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.